ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
investment factor · long-only model fund

Foundry Healthcare NetDebtFin Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FNEHHYPOTHETICAL MODEL
Since ’99
+10%
Expense Ratio
0.45%
placeholder
Holdings
95
cap-weighted
Inception
May 2021
placeholder
Full Sharpe
0.09
Ann. Return (LS)
1.1%
Ann. Volatility
12.0%
Max Drawdown
-49.2%
Test Sharpe ’19–26
-0.51
Test FF5 α (ann.)
-6.3%
vs Fama-French 5
Test FF5 α t-stat
-1.58
not significant
Monthly turnover
13%
of the long leg, per rebalance
Cumulative return (LS)
10%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.73
what this fund holds
Long leg ann. return
11.0%
buyable, long-only
Long-short Sharpe
0.09
requires shorting
Bottom bucket ann. return
9.9%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

95 of 95 · 100.0% of book
TickerCompanySectorMarket capWeight
1UNH
UNITEDHEALTH GROUP INCHealthcare$386.95B
25.59%
2GILD
GILEAD SCIENCES INCHealthcare$166.72B
11.03%
3BMY
BRISTOL MYERS SQUIBB COHealthcare$124.04B
8.20%
4SYK
STRYKER CORPHealthcare$122.63B
8.11%
5MDT
MEDTRONIC PLCHealthcare$106.50B
7.04%
6BSX
BOSTON SCIENTIFIC CORPHealthcare$65.44B
4.33%
7BDX
BECTON DICKINSON & COHealthcare$43.58B
2.88%
8TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTDHealthcare$37.30B
2.47%
9A
AGILENT TECHNOLOGIES INCHealthcare$37.13B
2.46%
10WAT
WATERS CORPHealthcare$36.23B
2.40%
11ALNY
ALNYLAM PHARMACEUTICALS INCHealthcare$35.71B
2.36%
12CNC
CENTENE CORPHealthcare$32.81B
2.17%
13DXCM
DEXCOM INCHealthcare$29.58B
1.96%
14DGX
QUEST DIAGNOSTICS INCHealthcare$23.32B
1.54%
15UTHR
UNITED THERAPEUTICS CORPHealthcare$22.74B
1.50%
16STE
STERIS PLCHealthcare$21.26B
1.41%
17SOLV
SOLVENTUM CORPHealthcare$14.08B
0.93%
18COO
COOPER COMPANIES INCHealthcare$13.99B
0.92%
19BTSG
BRIGHTSPRING HEALTH SERVICES INCHealthcare$13.71B
0.91%
20ELAN
ELANCO ANIMAL HEALTH INCHealthcare$12.90B
0.85%
21AXSM
AXSOME THERAPEUTICS INCHealthcare$11.84B
0.78%
22BAX
BAXTER INTERNATIONAL INCHealthcare$11.68B
0.77%
23PODD
INSULET CORPHealthcare$11.36B
0.75%
24TECH
BIO-TECHNE CORPHealthcare$11.29B
0.75%
25BRKR
BRUKER CORPHealthcare$8.86B
0.59%
26HQY
HEALTHEQUITY INCHealthcare$8.17B
0.54%
27PACS
PACS GROUP INCHealthcare$7.30B
0.48%
28TVTX
TRAVERE THERAPEUTICS INCHealthcare$5.27B
0.35%
29SHC
SOTERA HEALTH COHealthcare$5.06B
0.33%
30LIVN
LIVANOVA PLCHealthcare$4.43B
0.29%
31CON
CONCENTRA GROUP HOLDINGS PARENT INCHealthcare$4.04B
0.27%
32ICUI
ICU MEDICAL INCHealthcare$3.94B
0.26%
33NHC
NATIONAL HEALTHCARE CORPHealthcare$3.56B
0.24%
34OGN
ORGANON & COHealthcare$3.55B
0.23%
35XRAY
DENTSPLY SIRONA INCHealthcare$2.81B
0.19%
36GRDN
GUARDIAN PHARMACY SERVICES INCHealthcare$2.57B
0.17%
37NEOG
NEOGEN CORPHealthcare$2.24B
0.15%
38MD
PEDIATRIX MEDICAL GROUP INCHealthcare$2.15B
0.14%
39HTFL
HEARTFLOW INCHealthcare$2.15B
0.14%
40ADUS
ADDUS HOMECARE CORPHealthcare$2.14B
0.14%
41AXGN
AXOGEN INCHealthcare$2.12B
0.14%
42OMCL
OMNICELL INCHealthcare$2.09B
0.14%
43AUPH
AURINIA PHARMACEUTICALS INCHealthcare$2.05B
0.14%
44HRMY
HARMONY BIOSCIENCES HOLDINGS INCHealthcare$1.96B
0.13%
45NEO
NEOGENOMICS INCHealthcare$1.90B
0.13%
46UFPT
UFP TECHNOLOGIES INCHealthcare$1.87B
0.12%
47MRVI
MARAVAI LIFESCIENCES HOLDINGS INCHealthcare$1.87B
0.12%
48NVCR
NOVOCURE LTDHealthcare$1.84B
0.12%
49SRPT
SAREPTA THERAPEUTICS INCHealthcare$1.82B
0.12%
50TDOC
TELADOC HEALTH INCHealthcare$1.70B
0.11%
51ANAB
ANAPTYSBIO INCHealthcare$1.69B
0.11%
52FTRE
FORTREA HOLDINGS INCHealthcare$1.68B
0.11%
53PSNL
PERSONALIS INCHealthcare$1.61B
0.11%
54INNV
INNOVAGE HOLDING CORPHealthcare$1.56B
0.10%
55AHCO
ADAPTHEALTH CORPHealthcare$1.49B
0.10%
56BLFS
BIOLIFE SOLUTIONS INCHealthcare$1.42B
0.09%
57OMDA
OMADA HEALTH INCHealthcare$1.41B
0.09%
58AMN
AMN HEALTHCARE SERVICES INCHealthcare$1.36B
0.09%
59CNMD
CONMED CORPHealthcare$1.30B
0.09%
60ABSI
ABSCI CORPHealthcare$1.29B
0.09%
61COLL
COLLEGIUM PHARMACEUTICAL INCHealthcare$1.17B
0.08%
62NUTX
NUTEX HEALTH INCHealthcare$1.12B
0.07%
63BIOA
BIOAGE LABS INCHealthcare$1.01B
0.07%
64PCRX
PACIRA BIOSCIENCES INCHealthcare$1.01B
0.07%
65BVS
BIOVENTUS INCHealthcare$1.01B
0.07%
66ANNX
ANNEXON INCHealthcare$950M
0.06%
67PHAT
PHATHOM PHARMACEUTICALS INCHealthcare$873M
0.06%
68ZVRA
ZEVRA THERAPEUTICS INCHealthcare$755M
0.05%
69RIGL
RIGEL PHARMACEUTICALS INCHealthcare$750M
0.05%
70OMER
OMEROS CORPHealthcare$701M
0.05%
71EVH
EVOLENT HEALTH INCHealthcare$654M
0.04%
72TCMD
TACTILE SYSTEMS TECHNOLOGY INCHealthcare$648M
0.04%
73WEAV
WEAVE COMMUNICATIONS INCHealthcare$575M
0.04%
74NPCE
NEUROPACE INCHealthcare$548M
0.04%
75XOMA
XOMA ROYALTY CORPHealthcare$504M
0.03%
76VREX
VAREX IMAGING CORPHealthcare$444M
0.03%
77PBYI
PUMA BIOTECHNOLOGY INCHealthcare$434M
0.03%
78ENTA
ENANTA PHARMACEUTICALS INCHealthcare$400M
0.03%
79ABEO
ABEONA THERAPEUTICS INCHealthcare$399M
0.03%
80EBS
EMERGENT BIOSOLUTIONS INCHealthcare$394M
0.03%
81TBRG
TRUBRIDGE INCHealthcare$394M
0.03%
82FENC
FENNEC PHARMACEUTICALS INCHealthcare$365M
0.02%
83QTTB
Q32 BIO INCHealthcare$255M
0.02%
84SMTI
SANARA MEDTECH INCHealthcare$229M
0.02%
85AGEN
AGENUS INCHealthcare$209M
0.01%
86PDEX
PRO DEX INCHealthcare$183M
0.01%
87INFU
INFUSYSTEM HOLDINGS INCHealthcare$180M
0.01%
88ARCT
ARCTURUS THERAPEUTICS HOLDINGS INCHealthcare$172M
0.01%
89CUE
CUE BIOPHARMA INCHealthcare$126M
0.01%
90OPRX
OPTIMIZERX CORPHealthcare$126M
0.01%
91ICCC
IMMUCELL CORPHealthcare$101M
0.01%
92NRXS
NEURAXIS INCHealthcare$84M
0.01%
93FRMM
FORUM MARKETS INCHealthcare$83M
0.01%
94SNWV
SANUWAVE HEALTH INCHealthcare$55M
0.00%
95INKT
MINK THERAPEUTICS INCHealthcare$53M
0.00%

Full long-leg book as of July 2026 · cap-weighted · total market cap $1.51T. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

1 sectors
Healthcare
100.0%

Portfolio Style

Size × value map of the long-leg book

95 classified
Value
Blend
Growth
Large
Mid
Small
22%4
48%9
23%15
1%9
1%7
1%10
<1%12
<1%9
<1%5

Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 98% toward Large, 50% toward Growth. +4% unclassified (15 missing size/value). Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt98% → Large
SmallLarge
Value ↔ growth tilt50% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 95 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
4
Failed
2
Not tested
1
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

  • With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.

    Required
    >= 75.0%
    Actual
    65.0%
    Margin
    -10.0%
  • No more than 25% of total assets may be invested in the securities of any one issuer.

    Required
    <= 25.0%
    Actual
    25.6%
    Margin
    -0.6%

    Close to the line. The engine flags this verdict as one a routine data rebuild could flip. Read it as borderline rather than settled — the margin beside it is the whole story.

Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

1 verdict(s) sit within 1.0pp of their limit and can be flipped by a routine data rebuild; do not headline them, and always show the margin.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 95 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
1.0 (95% CI 0.7-1.3)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
10.0%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
1.04x
within
parametric
0.93x
within
cornish fisher
0.89x
within

The estimators agree, which is mild evidence the number isn’t an artefact of one method.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 2006
Before publication (pre-2006)
0.39
Sharpe · 6.1% p.a.
January 1999December 2006 · 96 mo
Since publication
-0.10
Sharpe · -1.0% p.a.
January 2007July 2026 · 235 mo
Change in Sharpe−0.49the return reversed sign — the published edge now runs the other way

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
73%
19 of 26 3-year windows made money
Worst window
-0.96
Sharpe, January 2023 – December 2025
January 1999July 2026
Median Sharpe
0.21
Dispersion
0.55
Best window
1.05

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.14.7%-22.9%
3 yearsp.a.4.0%-12.7%
5 yearsp.a.0.9%-9.4%
10 yearsp.a.8.1%-4.0%
Since inceptionp.a.10.3%0.3%
Calendar years
YearLong legLong-short
20267 mo-3.7%-15.3%
202513.5%-11.1%
20243.7%-5.8%
2023-7.7%-18.4%
2022-7.4%-3.1%
202135.3%25.1%
202012.6%-6.5%
201921.6%-6.2%
201812.0%14.8%
201721.4%1.7%
2016-9.7%-3.1%
201514.0%7.8%
201418.8%-11.7%
201343.1%-3.8%
201219.6%-5.2%
201114.1%12.5%
201014.0%10.5%
200921.2%6.3%
2008-28.4%-14.2%
20078.9%8.5%
200614.1%15.5%
20055.6%-13.0%
20042.3%-0.5%
200348.9%31.5%
2002-21.5%0.7%
20014.3%23.9%
200033.9%-30.8%
199919.6%29.8%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FNEH
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.45% (placeholder)
Inception2021-05-13 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$1.51T

Methodology

The Foundry Healthcare NetDebtFin Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a NetDebtFin signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.